# Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer

> **NCT04271384** · PHASE2 · COMPLETED · sponsor: **Hospital Israelita Albert Einstein** · enrollment: 25 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Stage I

## Interventions

- **COMBINATION_PRODUCT:** nivolumab

## Key facts

- **NCT ID:** NCT04271384
- **Lead sponsor:** Hospital Israelita Albert Einstein
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-12
- **Primary completion:** 2023-11-15
- **Final completion:** 2023-11-15
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04271384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04271384, "Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04271384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*